AMJ Global Technology 3Q 2025: Revenue $232 EPS $(0.01) — 10-Q Summary

About this update from Amj Global Technology

AMJ Global Technology reported third-quarter 2025 results marked by nascent revenue and a wider net loss as the company recorded an impairment charge. Revenue for the quarter was $232 up from $8 in the year-ago quarter, while net loss widened to $934274 and diluted loss per share was $(0.01). Financial Highlights Revenue: $232 for 3Q 2025, up from $8 in 3Q 2024 (+$224 YoY), driven by related-party Medicare revenue sharing. Net income: Net loss $934,274 for 3Q 2025, compared with net loss $50,825 in 3Q 2024; the wider loss was driven by an $886,232 impairment. Diluted EPS: $(0.01) for 3Q 2025 vs $(0.00) for 3Q 2024. Business Highlights Revenue momentum: The company recognized minimal related-party revenue from Medicare revenue-sharing, increasing from $8 to $232 for the quarter, indicating early-stage commercial receipts. Strategic shift: AMJ moved its operational focus from mobile software to holistic tech-based health treatments and sports health, targeting PTSD and neurodegenerative care. Partnerships and IP actions: The company executed and later unwound several software and asset arrangements, including cancellation of an ElephantSqlDB® equity issuance and multiple unwind agreements. Service channel development: Management is pursuing Medicare, life and annuity channels through revenue-sharing agreements with related parties to develop recurring referral revenue streams. Original SEC Filing: This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

View stock analysis, news, and events for Amj Global Technology